SRR8518385
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.460
- INTERFERON_GAMMA_RESPONSE+0.460
- COMPLEMENT+0.420
- PROTEIN_SECRETION+0.420
- KRAS_SIGNALING_UP+0.400
- INFLAMMATORY_RESPONSE+0.390
- ANGIOGENESIS+0.360
- IL6_JAK_STAT3_SIGNALING+0.360
- IL2_STAT5_SIGNALING+0.340
- ANDROGEN_RESPONSE+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.510
- NOTCH_SIGNALING-0.330
- WNT_BETA_CATENIN_SIGNALING-0.290
- APICAL_SURFACE-0.240
- ESTROGEN_RESPONSE_EARLY-0.220
- DNA_REPAIR-0.200
- MYOGENESIS-0.200
- CHOLESTEROL_HOMEOSTASIS-0.160
- GLYCOLYSIS-0.160
- APICAL_JUNCTION-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518178 | — | A | 0.866 |
| 2 | 2aefe8ef-5ffd-4c0d-8550-2573eb6fb051 | — | — | 0.855 |
| 3 | MNG561 | — | — | 0.833 |
| 4 | BS_ZV68CES9 | Med | Medulloblastoma | 0.829 |
| 5 | SRR8613745 | — | A | 0.824 |
| 6 | SRR8518236 | — | A | 0.819 |
| 7 | TCGA-50-5049-01A-01R-1628-07 | — | cohortA1 | 0.819 |
| 8 | BS_V72GX2AZ | low-grade glioma | — | 0.814 |
| 9 | TCGA-E9-A1N4-01A-11R-A14M-07 | — | A | 0.804 |
| 10 | SRR4195658 | — | — | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |